CRISPR Therapeutics AG
CRSP
Positions held
Your positionsCRSP isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- CRISPR Therapeutics operates in the rapidly advancing biotechnology sector, focusing on gene editing technologies that have the potential to revolutionize treatment for various diseases.
- Revenue increased by 900% compared to the prior quarter, reaching $10 million from $1 million.
- Operating margin improved to -1172.7%, showing signs of operational efficiency despite ongoing challenges.
- The company has a high debt-to-equity ratio of 44.874, indicating potential financial risk and reliance on debt financing.
- Net income for 2026-Q1 was -122.931 million, reflecting ongoing losses as the company continues to invest heavily in R&D.
- Profit margin remains at 0.0%, highlighting the lack of profitability amidst significant operational costs.
Fundamentals
| Market cap | $4.88B | Enterprise value | $3.30B | Trailing P/E | — | Forward P/E | -14.42 |
| PEG | — | Price / book | 2.79 | Beta | 1.76 | Dividend yield | 0.00% |
| Revenue growth | 10.4% | Earnings growth | — | Gross margin | 0.0% | Operating margin | -11.3% |
| Profit margin | 0.0% | ROE | -26.1% | ROA | -14.2% | Debt / equity | 0.45 |
| Current ratio | 17.85 | Free cash flow | -$215.85M | Analyst recommendation | buy | Mean target | $87.56 |
| 52w high | $78.00 | 52w low | $44.12 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | $10.0M | $1.0M | $0.0M | $0.0M | $0.0M |
| Op margin | -1172.7% | -13024.8% | — | — | — |
| Net income | -$91.2M | -$123M | -$131M | -$106M | -$209M |
| Gross margin | -302.7% | -4494.9% | — | — | — |
| Gross profit | -$30.3M | -$44.9M | -$53.7M | -$57.1M | -$45.2M |
| Operating income | -$117M | -$130M | -$155M | -$132M | -$229M |
- Revenue +900% vs prior quarter ($10M vs $1.0M).
- Gross margin -302.7% (was -4494.9% prior quarter).
- Operating margin expanded to -1172.7%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $0.0M | $35.0M | $370M | $0.4M |
| Op margin | — | -1333.0% | -60.1% | -154394.7% |
| Net income | -$582M | -$366M | -$154M | -$650M |
| Gross margin | — | -244.8% | 64.8% | -25186.7% |
| Gross profit | -$213M | -$85.7M | $240M | -$110M |
| Operating income | -$665M | -$467M | -$223M | -$673M |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-08 · AbbVie's Temab-A Gets Two FDA Breakthrough Therapy Tags in Cancer
2026-10-08 · Ultragenyx to Sell Rare Pediatric Disease PRV for $210M to Boost Cash
2026-10-08 · CRISPR Therapeutics to Present Late-Breaking Data at the American Heart Association (AHA) Scientific Sessions 2026
2026-10-07 · Is Agilon Health (AGL) Stock Outpacing Its Medical Peers This Year?
2026-10-06 · CRISPR Therapeutics AG (CRSP) Stock Slides as Market Rises: Facts to Know Before You Trade
2026-10-05 · Wall Street Bulls Look Optimistic About CRISPR Therapeutics (CRSP): Should You Buy?
2026-09-30 · Anthropic Just Made a CRISPR-Like Discovery. What It Actually Means for CRSP Stock Investors.
2026-09-29 · Temporary Weakness in Intellia Stock Seems Like a Buying Opportunity
2026-09-29 · CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know
2026-09-29 · CRISPR Therapeutics Has 2 Key Catalysts Coming by the End of 2026. Is the Market Underestimating Them?
2026-09-25 · CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: Here's Why
Price (daily)
Full chart · RSI · MACD · patterns